Armando Anido agrees to leave Auxilium; Adrian Adams new CEO
This article was originally published in Scrip
Auxilium Pharmaceuticals, a specialty biopharmaceutical company, has appointed Adrian Adams president and CEO. Mr Adams succeeds Armando Anido, who, after discussions with the company's board of directors, has agreed to step down as CEO and president, and has resigned from the board. Mr Adams has over 30 years' experience in the pharmaceutical industry, most recently serving as chair and CEO of Neurologix.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.